Branched-long-chain monomethyl fatty acids (BLCFA) are
consumed
daily in significant amounts by humans in all stages of life. BLCFA
are absorbed and metabolized in human intestinal epithelial cells
and are not only oxidized for energy. Thus far, BLCFA have been revealed
to possess versatile beneficial bioactivities, including cytotoxicity
to cancer cells, anti-inflammation, lipid-lowering, reducing the risk
of metabolic disorders, maintaining normal β cell function and
insulin sensitivity, regulation of development, and mitigating cerebral
ischemia/reperfusion injury. However, compared to other well-studied
dietary fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), BLCFA has received disproportionate attention despite
their potential importance. Here we outlined the major food sources,
estimated intake, absorption, and metabolism in human cells, and bioactive
properties of BLCFA with a focus on the bioactive mechanisms to advocate
for an increased commitment to BLCFA investigations. Humans were estimated
to absorb 6–5000 mg of dietary BLCFA daily from fetus to adult.
Notably,
iso
-15:0 inhibited the growth of prostate
cancer, liver cancer and T-cell non-Hodgkin lymphomas in rodent models
at the effective doses of 35–105 mg/kg/day, 70 mg/kg/day, and
70 mg/kg/day, respectively. Feeding formula prepared with 20% w/w
BLCFA mixture to neonatal rats with enterocolitis mitigated the intestine
inflammation.
Iso
-15:0 at doses of 10, 40, and 80
mg/kg relieved brain ischemia/reperfusion injury in rats. In the future,
it is crucial to conduct research to establish the epidemiology of
BLCFA intake and their impacts on health outcomes in humans as well
as to fully uncover the underlying mechanisms for their bioactivities.